Abstract
A patient-reported outcome is directly reported by the patient without interpretation of the patient's response by anyone else. It refers to the patient's health (symptoms and feelings), quality of life, or functional status associated with health care or treatment. Patient-reported outcome measures (PROMs) are defined as the tools or instruments that are used to measure patient-reported outcomes. Health-related quality of life has been the most studied psychosocial PROM in food allergy, using validated questionnaires. In drug allergy, PROMs are useful in capturing patients' experiences of potential allergic reactions, including subjective symptoms such as headache, dizziness, or fatigue. Patient-reported outcome measures can also help differentiate true allergies from side effects or other nonallergic reactions and inform decisions about drug challenges and de-labeling strategies. Ensuring the chosen tool is validated for the specific allergy context is crucial for accurate data collection. Integrating patient-reported experiences alongside traditional methods can lead to more accurate assessments and personalized care.
Original language | English (US) |
---|---|
Pages (from-to) | 2591-2598 |
Number of pages | 8 |
Journal | Journal of Allergy and Clinical Immunology: In Practice |
Volume | 12 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2024 |
Funding
Conflicts of interest: A. Anagnostou reports institutional funding from Aimmune and Novartis; advisory board membership in DBV Technologies and Novartis; and receiving consultation/speaker fees from ALK, Adelphi , Aimmune Therapeutics , and Genentech . J. Dantzer reports grant funding from the National Institutes of Health / National Institute of Allergy and Infectious Diseases (K23AI159143-01A1). E.J. Phillips receives funding from Grants R01HG010863, R01AI152183, U01AI154659, and R13AR082704. The rest of the authors declare that they have no relevant conflicts of interest. Conflicts of interest: A. Anagnostou reports institutional funding from Aimmune and Novartis; advisory board membership in DBV Technologies and Novartis; and receiving consultation/speaker fees from ALK, Adelphi, Aimmune Therapeutics, and Genentech. J. Dantzer reports grant funding from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (K23AI159143-01A1). E.J. Phillips receives funding from NIH grants R01HG010863, R01AI152183, U01AI154659, and R13AR082704. The rest of the authors declare that they have no relevant conflicts of interest.
Keywords
- Drug allergy
- Food allergy
- Health-related quality of life
- Patient-reported outcome measures
- Severe cutaneous adverse drug reactions
ASJC Scopus subject areas
- Immunology and Allergy